Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Veru (VERU) 2.09% +0.85, NovaDel Pharma ...
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...
Veru Inc.’s Promising Phase IIb Results Suggest Investment Opportunity with Enobosarm’s Weight Management Potential
William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...
STAT3d
Veru says its drug preserved lean mass in patients taking Wegovy
An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...
BioSpace3d
Veru’s Drug Spares Lean Mass in Overweight, Obese Adults on Wegovy—Is It Enough?
Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...
FierceBiotech3d
Veru's drug conserves muscle mass for older patients taking Novo's Wegovy in phase 2 trial
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
Veru's experimental drug helps older obese patients on Wegovy preserve muscle
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
BioPharma Dive3d
Muscle-building drug improves body composition in obesity trial, Veru says
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
STAT3d
U.S. health agencies see some chaos — but an FDA approval gets through
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.